Anika Therapeutics (ANIK) Cash & Current Investments (2010 - 2026)

Anika Therapeutics (ANIK) has reported Cash & Current Investments for 17 consecutive years, with $38.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 50.19% year-over-year to $38.4 million in Q2 2026; TTM through Jun 2026 was $38.4 million, a 50.19% decrease from a year earlier, with the FY2025 full-year figure at $81.2 million, up 2.46% from the prior year.
• Cash & Current Investments was $38.4 million for Q2 2026 at Anika Therapeutics, down from $66.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $123.6 million in Q2 2022 and troughed at $38.4 million in Q2 2026.
• A 5-year average of $93.6 million and a median of $95.8 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 34.04% in 2022 and slumped 50.19% in 2026, its largest moves.
• Over 5 years, Cash & Current Investments stood at $121.0 million in 2022, then fell by 21.38% to $95.1 million in 2023, then fell by 16.7% to $79.2 million in 2024, then climbed by 2.46% to $81.2 million in 2025, then plunged by 52.68% to $38.4 million in 2026.
• The last three Cash & Current Investments figures came in at $38.4 million (Q2 2026), $66.8 million (Q1 2026), and $81.2 million (Q4 2025), per Business Quant data.